Management of Medication-Induced Hot Flashes
Pharmacological Interventions
- SNRIs like duloxetine reduce hot flash frequency by 61% at 75 mg/day compared to 27% with placebo, making it an evidence-based treatment for vasomotor symptoms in patients with a history of hot flashes, as recommended by the National Comprehensive Cancer Network 1, 2
- Duloxetine and venlafaxine are recommended as first-line nonhormonal therapies for hot flashes in multiple clinical guidelines, including those from the National Comprehensive Cancer Network, for patients experiencing hot flashes due to various medical conditions 3, 4
- The mechanism of SNRIs in treating hot flashes appears independent of their antidepressant effects and works rapidly (within 1 week) in patients taking these medications for hot flash management 2
- Gabapentin 900 mg/day reduces hot flash severity by 46% and has no drug interactions with either lamotrigine or duloxetine, making it a suitable adjunctive therapy for patients with medication-induced hot flashes, as suggested by the Journal of the National Comprehensive Cancer Network 3, 6, 7
Clinical Decision-Making
- The American College of Clinical Pharmacology recommends confirming the temporal relationship between medication initiation and hot flash worsening to identify the causative agent, which is crucial in patients experiencing hot flashes after starting a new medication 5
- The National Comprehensive Cancer Network suggests considering a trial discontinuation of the suspected offending medication, such as lamotrigine, if the indication permits, to assess the impact on hot flashes in patients with a suspected medication-induced cause 5
- The American Society of Clinical Oncology advises against discontinuing duloxetine abruptly, as SNRIs require gradual tapering to prevent discontinuation syndrome, and stopping it would remove a therapeutic agent for hot flashes in patients benefiting from this medication 1, 2